Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells

J Nephrol. 2011 Mar-Apr;24(2):218-24. doi: 10.5301/jn.2010.5785.

Abstract

Background: Recent studies have identified high glucose as a potent stimulus for the intracellular synthesis of angiotensin II. However, the exact roles of angiotensin II and angiotensin II type 1 receptor blockers (ARB) in high-glucose-induced renal tubular function remain unclear.

Methods: N-Acetyl-beta-glucosaminidase (NAG), angiotensin II and 8-hydroxy-2'-deoxyguanosine (8-OHdG) concentrations in renal proximal tubular epithelial cells (RPTECs) with or without high glucose/ARB were determined using a modified commercial procedure. The changes of p22phox and cytoplasmic inhibitory kappa B (IkB) protein levels in RPTECs were measured using Western blotting.

Results: High-glucose treatment (4x10-2 mol/L) significantly increased NAG release, angiotensin II concentrations in cell lysates and 8-OHdG and p22phox protein levels compared with those in regular glucose medium (1.75x10(-2) mol/L). ARBs (candesartan, olmesartan or valsartan; 1x10(-9)-10(-7) mol/L) showed a significant reduction in high-glucose-induced NAG, 8-OHdG and p22phox protein levels in RPTECs. Significant decreases of cytoplasmic IkB protein levels were observed in the high-glucose-treated group in RPTECs. ARBs markedly reversed high-glucose-induced reduction of IkB protein levels in RPTECs.

Conclusions: ARBs reduce high-glucose-induced oxidative stress in RPTECs possibly via blockade of intracellular as well as extracellular AT1 receptor signaling, which possibly protects renal tubular cell function during diabetic nephropathy.

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Cells, Cultured
  • Deoxyguanosine / analogs & derivatives
  • Deoxyguanosine / metabolism
  • Dose-Response Relationship, Drug
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism*
  • Epithelial Cells / pathology*
  • Glucose / adverse effects*
  • Glucose / pharmacology
  • Humans
  • I-kappa B Proteins / metabolism
  • Kidney Tubules, Proximal / drug effects
  • Kidney Tubules, Proximal / metabolism*
  • Kidney Tubules, Proximal / pathology*
  • NADPH Oxidases / metabolism
  • Oxidative Stress / drug effects
  • Receptors, Angiotensin / metabolism*
  • Signal Transduction / drug effects
  • beta-N-Acetyl-Galactosaminidase / metabolism

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • I kappa B beta protein
  • I-kappa B Proteins
  • Receptors, Angiotensin
  • 8-Hydroxy-2'-Deoxyguanosine
  • NADPH Oxidases
  • CYBA protein, human
  • beta-N-Acetyl-Galactosaminidase
  • Deoxyguanosine
  • Glucose